Abstract:figure legend The hallmark of cardiac disease is autonomic dysregulation, characterised by a state of chronic sympathoexcitation. Neuropeptide‐Y (NPY) is a sympathetic co‐transmitter that is released by sympathetic neurons and circulating venous levels are elevated in a range of cardiac disease, such as myocardial infarction and chronic heart failure. NPY has direct effects on cardiomyocytes, vascular smooth muscle cells and autonomic nerves through its Y receptors, resulting in adverse cardiac remodelling, pro‐arrhythmic electrophysiological changes, vasoconstriction and parasympathetic inhibition. Large prospective cohort studies have demonstrated that these effects ultimately lead to adverse cardiac events and increased mortality in patients. An understanding of the role of co‐transmitters such as NPY may ultimately lead to novel therapeutic targets and biomarkers to improve risk stratification and prognostication in patients with cardiac disease. William Bayliss and Ernest Starling are not only famous as pioneers in cardiovascular physiology, but also responsible for the discovery of the first hormone (from the Greek 'excite or arouse'), the intestinal signalling molecule and neuropeptide secretin in 1902. Our research group focuses on neuropeptides and neuromodulators that influence cardiovascular autonomic control as potential biomarkers in disease and tractable targets for therapeutic intervention. Acute myocardial infarction (AMI) and chronic heart failure (CHF) result in high levels of cardiac sympathetic stimulation, which is a poor prognostic indicator. Although beta‐blockers improve mortality in these conditions by preventing the action of the neurotransmitter noradrenaline, a substantial residual risk remains. Recently, we have identified the sympathetic co‐transmitter neuropeptide‐Y (NPY) as being released during AMI, leading to larger infarcts and life‐threatening arrhythmia in both animal models and patients. Here, we discuss recently published data demonstrating that peripheral venous NPY levels are associated with heart failure hospitalisation and mortality after AMI, and all cause cardiovascular mortality in CHF, even when adjusting for known risk factors (including brain natriuretic peptide). We have investigated the mechanistic basis for these observations in human and rat stellate ganglia and cardiac tissue, manipulating NPY neurochemistry at the same time as using state‐of‐the‐art imaging techniques, to establish the receptor pathways responsible for NPY signalling. We propose NPY as a new mechanistic biomarker in AMI and CHF patients and aim to determine whether specific NPY receptor blockers can prevent arrhythmia and attenuate the development of heart failure.

Neuropeptide Y. A novel sympathetic stress hormone and more

NPY System in Stress and Major Depressive Disorder

Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome

The homeostatic role of neuropeptide Y in immune function and its impact on mood and behaviour

Feedforward inhibition of stress by brainstem neuropeptide Y neurons

Neuropeptide Y, ubiquitous and elusive

Prenatal Stress, Anxiety and Depression: a Mechanism Involving CRH Peptide Family.

Intranasal administration of neuropeptide Y significantly antagonized stress-induced colonic dysmotility via central GABAA receptors in male rats

Bayliss Starling Prize Lecture 2023: Neuropeptide‐Y being 'unsympathetic' to the broken hearted

[Neuropeptides Y, YY, PP and their clinical significance]

Chronic psychosocial stress alters NPY system: different effects in rat and tree shrew.

Physiological and Therapeutic Roles of Neuropeptide Y on Biological Functions

NPY and cardiac diseases

Neuropeptide Y: Direct vasoconstrictor and facilitatory effects on P2X1 receptor-dependent vasoconstriction in human small abdominal arteries

Neuropeptide Y Is an Immunomodulatory Factor: Direct and Indirect

Activation of NPY Receptors in the BLA Inhibits Projections to the Bed Nucleus of the Stria Terminalis and Buffers Stress-Induced Decreases in Social Interaction in Male Rats

Human sympathetic neuronal discharge and recruitment patterns regulate neuropeptide Y bioavailability

Receptors for NPY in peripheral tissues bioassays

Stress, Neuropeptides and Gastric Mucosa

Neuropeptide Y and its receptors as potential therapeutic drug targets

Role of Brain NUCB2/nesfatin-1 in Stress and Stress-Related Gastrointestinal Disorders